Literature DB >> 21979862

Emerging techniques to treat corneal neovascularisation.

J Menzel-Severing1.   

Abstract

Neovascularisation is a major cause of visual loss in a number of ophthalmic diseases. This review aims to outline the basic regulators of vessel growth in corneal neovascularisation. An understanding of the underlying principles of physiological and pathophysiological vascular development helps to appreciate current approaches to prevent or treat corneal neovascularisation. Options for future interventions will be discussed in the light of recent evidence provided by animal models of corneal neovascularisation.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21979862      PMCID： PMC3259583          DOI： 10.1038/eye.2011.246

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


  118 in total

1.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.

Authors:  D Gospodarowicz; J A Abraham; J Schilling
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Tumor growth and neovascularization: an experimental model using the rabbit cornea.

Authors:  M A Gimbrone; R S Cotran; S B Leapman; J Folkman
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

4.  Corneal neovascularization as studied by scanning electron microscopy of vascular casts.

Authors:  P C Burger; D B Chandler; G K Klintworth
Journal:  Lab Invest       Date:  1983-02       Impact factor: 5.662

5.  Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors:  D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  Tumor-induced angiogenesis: lack of inhibition by irradiation.

Authors:  R Auerbach; R Arensman; L Kubai; J Folkman
Journal:  Int J Cancer       Date:  1975-02-15       Impact factor: 7.396

7.  Anti-angiogenic role of angiostatin during corneal wound healing.

Authors:  Eric Gabison; Jin-Hong Chang; Everardo Hernández-Quintela; Joel Javier; Paul C S Lu; Hongqing Ye; Tomoko Kure; Takuji Kato; Dimitri T Azar
Journal:  Exp Eye Res       Date:  2004-03       Impact factor: 3.467

8.  Human endothelial cells are chemotactic to endothelial cell growth factor and heparin.

Authors:  V P Terranova; R DiFlorio; R M Lyall; S Hic; R Friesel; T Maciag
Journal:  J Cell Biol       Date:  1985-12       Impact factor: 10.539

9.  Endostatin/collagen XVIII--an inhibitor of angiogenesis--is expressed in cartilage and fibrocartilage.

Authors:  Thomas Pufe; Wolf J Petersen; Nicolai Miosge; Mary B Goldring; Rolf Mentlein; Deike J Varoga; Bernhard N Tillmann
Journal:  Matrix Biol       Date:  2004-08       Impact factor: 11.583

10.  Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny.

Authors:  L Pardanaud; F Yassine; F Dieterlen-Lievre
Journal:  Development       Date:  1989-03       Impact factor: 6.868
View more
  8 in total

1.  Anti-apoptosis effects of vascular endothelial cadherin in experimental corneal neovascularization.

Authors:  Gao-Qin Liu; Hong-Ya Wu; Jing Xu; Meng-Jiao Wang; Pei-Rong Lu; Xue-Guang Zhang
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

Review 2.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

3.  lncRNA MIAT suppression alleviates corneal angiogenesis through regulating miR-1246/ACE.

Authors:  Yanhui Bai; Weiqun Wang; Youmei Zhang; Fengyan Zhang; Haohao Zhang
Journal:  Cell Cycle       Date:  2019-03-05       Impact factor: 4.534

4.  Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.

Authors:  Che-Yi Chang; Ming-Chen Wang; Takuya Miyagawa; Zhi-Yu Chen; Feng-Huei Lin; Ko-Hua Chen; Guei-Sheung Liu; Ching-Li Tseng
Journal:  Int J Nanomedicine       Date:  2016-12-30

5.  Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization Via Inhibition of VEGF Production.

Authors:  Takuya Miyagawa; Zhi-Yu Chen; Che-Yi Chang; Ko-Hua Chen; Yang-Kao Wang; Guei-Sheung Liu; Ching-Li Tseng
Journal:  Pharmaceutics       Date:  2020-04-28       Impact factor: 6.321

6.  Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report.

Authors:  Mariela Grossi Donato; Elias Donato; Marina Álvares de Campos Cordeiro; Matheus Martins de Andrade; João Alberto Holanda de Freitas
Journal:  Rom J Ophthalmol       Date:  2021 Jul-Sep

Review 7.  Role of Matrix Metalloproteinases in the Pathogenesis of Traumatic Brain Injury.

Authors:  P M Abdul-Muneer; Bryan J Pfister; James Haorah; Namas Chandra
Journal:  Mol Neurobiol       Date:  2015-11-05       Impact factor: 5.682

8.  Prophylactic effect of topical silica nanoparticles as a novel antineovascularization agent for inhibiting corneal neovascularization following chemical burn.

Authors:  Mehrdad Mohammadpour; Mahmoud Jabbarvand; Hassan Hashemi; Elham Delrish
Journal:  Adv Biomed Res       Date:  2015-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.